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Facioscapulohumeral dystrophy, or FSHD, is the third most common form of muscular dystrophy 
with an estimated incidence of 1 in 14,000 births. It causes progressive weakness and wasting in 
skeletal muscles, particularly muscles of the face, shoulders, and arms. The age of FSHD onset is 
highly variable, but typically occurs between the second and third decades of life and there is a wide 
range in the severity of this autosomal dominant disease. 
Approximately ten years ago, it was discovered that DUX4 gene copies exhibit reduced epigenetic 
repression in individuals with FSHD compared to healthy controls. However, it was extremely difficult 
to find molecular evidence of DUX4 mRNA or protein in FSHD muscle; therefore, the link between 
genotype and phenotype remained elusive. In 2010, a team lead by Dr. Stephen Tapscott of the 
Human Biology Division found that DUX4 is normally highly expressed in the testes of healthy 
individuals but not in healthy skeletal muscle, whereas very low amounts of DUX4 could be detected 
in the skeletal muscle of individuals with FSHD. Finally, in last month’s issue ofDevelopmental Cell, 
postdoctoral fellows Drs. Linda Geng and Zizhen Yao, along with other members of the Tapscott Lab 
and outside collaborators, discovered the fundamental mechanism linking DUX4to the 
pathophysiology of FSHD. In short, the authors demonstrated that DUX4 is a transcription activator 
that stimulates aberrant gene expression in FSHD muscle. 
Geng et al. showed that DUX4 stimulates a massive upregulation of genes in healthy primary 
muscle cells, including β-defensin 3, retrotransposons, genes involved in RNA transcription and 
processing, and genes involved in stem cell and germ cell function (e.g., gamete/spermatogenesis). 
This was the first indication that DUX4 is a transcription activator. When the authors then examined 
transcripts from FSHD muscle cells, they readily detected transcripts from DUX4 target genes that 
were not present in healthy muscle. Many of these gene products may contribute to the 
pathophysiology of FSHD in diverse ways that remain to be established. For example, the authors 
showed that β-defensin 3 can inhibit genes involved in the differentiation of muscle tissue, whereas 
the misexpression of testis proteins in FSHD skeletal muscle may cause pathology by stimulating an 
adaptive (auto) immune response. This study has also provided a remarkable number of putative  
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biomarkers and therapeutic targets for FSHD, all of which underscore the importance of 
understanding the disease mechanism. 
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Modified from manuscript 
A pairwise comparison of the number and intensity of 
transcripts that are upregulated (blue dots) or 
downregulated (red dots) in healthy primary muscle cells 
upon expression of DUX4 with reference to a negative 
control (GFP). 
 
